Evaluation of a Claims-based Algorithm for the Identification of Transthyretin-mediated Amyloidosis (ATTR) Amyloidosis in Medical Records

Launched by YALE UNIVERSITY · Sep 24, 2020

Keywords

ClinConnect Summary

This clinical trial is studying a new way to identify a condition called Transthyretin Amyloidosis (ATTR) using a special algorithm. The goal is to see how well this algorithm can find patients who might have ATTR amyloidosis by looking at their medical records. This is important because early diagnosis can help people get the right treatment sooner.

To participate in the trial, you should be between the ages of 65 and 74 and identified by the algorithm as possibly having ATTR. You should also be receiving care at Yale New Haven Health System (YNHHS). If you meet these criteria, researchers will reach out to you to discuss further tests that could confirm whether or not you have this condition. Please note that if you have opted out of research or are pregnant, you won't be eligible for this study. This trial is currently looking for participants, and your involvement could help improve how ATTR is diagnosed in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• * Identified by the ATTR diagnostic algorithm and matched by Yale's list of potential subjects defined as:
• • 1. subjects within the claims dataset that are predicted to be at risk of having ATTR who are also being managed within YNHHS
• • 2. patients who need to be contacted and offered additional clinical evaluation to determine whether they have a diagnosis of ATTR (non-hereditary or Hereditary ATTR amyloidosis).
• Exclusion Criteria:
• • Patients who have opted out of research in the Epic system will be excluded entirely from the study
• • Patients who are pregnant or who may become pregnant